Numab Therapeutics AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Numab Therapeutics AG - overview
Established
2011
Location
-, -, Switzerland
Primary Industry
Biotechnology
About
Numab Therapeutics AG, based in Switzerland, focuses on developing innovative multi-specific antibody-based immunotherapies targeting inflammation and cancer, utilizing proprietary platforms to create customized therapeutic solutions. Founded in 2011 and headquartered in Zurich, Switzerland, Numab Therapeutics AG specializes in immunotherapy development. The company has successfully raised CHF 50. 000 mn in its SERIES C funding round as of January 9, 2025, led by notable investors including Cormorant Asset Management and HBM Partners.
Peter Lichtlen is the founder, with David Urech serving as CEO. Numab Therapeutics AG specializes in developing multi-specific antibody-based immunotherapies with a focus on inflammation and cancer. Their flagship products leverage two proprietary platforms, λ-Cap™ and MATCH™, aiding in the creation of tailored therapeutic options. Notably, their lead candidate NM26 targets IL-4Rα and IL-31 for atopic dermatitis and related disorders.
The company collaborates with pharmaceutical partners like Kaken Pharmaceutical Co. , Ltd in Japan to enhance product development and reach key markets across Europe, North America, and Asia. Numab Therapeutics AG generates revenue through strategic collaborations with pharmaceutical companies for therapy development and commercialization. Their revenue model is primarily B2B, relying on partnerships that fund research and clinical development in return for licensing rights or profit-sharing agreements.
This approach is critical for advancing their pipeline and ensuring a stable revenue flow as their products progress through clinical trials. Numab Therapeutics AG plans to further its growth by launching new products, including advancing NM26 through clinical trials. The recent CHF 50. 000 mn raised in SERIES C funding will support these initiatives, enhancing their capacity for product development.
The company aims to expand its market presence in Europe, North America, and Asia by strategically collaborating with pharmaceutical partners and advancing their therapeutic offerings in these regions.
Current Investors
Mitsubishi UFJ Capital, Eisai Co, 3SBio Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.numab.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Numab Therapeutics AG - employee data
Numab Therapeutics AG - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.